330 related articles for article (PubMed ID: 15736185)
21. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
22. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
[TBL] [Abstract][Full Text] [Related]
23. Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population.
Scott F; Peters H; Bonifacio M; McLennan A; Boogert A; Kesby G; Anderson J
Aust N Z J Obstet Gynaecol; 2004 Jun; 44(3):205-9. PubMed ID: 15191443
[TBL] [Abstract][Full Text] [Related]
24. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
[TBL] [Abstract][Full Text] [Related]
25. First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice.
Stenhouse EJ; Crossley JA; Aitken DA; Brogan K; Cameron AD; Connor JM
Prenat Diagn; 2004 Oct; 24(10):774-80. PubMed ID: 15503268
[TBL] [Abstract][Full Text] [Related]
26. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a regional experience from Germany.
Soergel P; Pruggmayer M; Schwerdtfeger R; Muhlhaus K; Scharf A
Fetal Diagn Ther; 2006; 21(3):264-8. PubMed ID: 16601335
[TBL] [Abstract][Full Text] [Related]
27. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-trimester screening for trisomy 21.
Wright D; Abele H; Baker A; Kagan KO
Ultrasound Obstet Gynecol; 2011 Sep; 38(3):309-13. PubMed ID: 21400623
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the impact of PAPP-A, free β-hCG and nuchal translucency thickness on the advanced first trimester screening.
Berktold L; von Kaisenberg CS; Hillemanns P; Vaske B; Schmidt P
Arch Gynecol Obstet; 2013 Mar; 287(3):413-20. PubMed ID: 23080546
[TBL] [Abstract][Full Text] [Related]
29. First trimester predictors of adverse pregnancy outcomes.
Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
[TBL] [Abstract][Full Text] [Related]
30. Modeling Down syndrome screening performance using first-trimester serum markers.
Koster MP; Wortelboer EJ; Stoutenbeek P; Visser GH; Schielen PC
Ultrasound Obstet Gynecol; 2011 Aug; 38(2):134-9. PubMed ID: 21800388
[TBL] [Abstract][Full Text] [Related]
31. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
Chen X; Chang Y; Cui HY; Ren CC; Yu BY
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
[TBL] [Abstract][Full Text] [Related]
32. Prospective study evaluating performance of first-trimester combined screening for trisomy 21 using repeat sampling of maternal serum markers PAPP-A and free β-hCG.
Ekelund C; Wright D; Ball S; Kirkegaard I; Nørgaard P; Sørensen S; Friis-Hansen L; Jørgensen FS; Tørring N; Bech BH; Petersen OB; Tabor A
Ultrasound Obstet Gynecol; 2012 Sep; 40(3):276-81. PubMed ID: 22807155
[TBL] [Abstract][Full Text] [Related]
33. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO; Anderson JM; Anwandter G; Neksasova K; Nicolaides KH
Prenat Diagn; 2008 Dec; 28(13):1209-13. PubMed ID: 19039823
[TBL] [Abstract][Full Text] [Related]
34. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
[TBL] [Abstract][Full Text] [Related]
35. The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies.
Maymon R; Sharony R; Grinshpun-Cohen J; Itzhaky D; Herman A; Reish O
J Perinat Med; 2005; 33(5):392-8. PubMed ID: 16238533
[TBL] [Abstract][Full Text] [Related]
36. [Cross-validation of the first trimester screening algorithm of the FMF London on 38,700 pregnancies in Germany].
Lüthgens K; Abele H; Alkier R; Hoopmann M; Kagan KO
Ultraschall Med; 2011 Aug; 32(4):367-72. PubMed ID: 21667432
[TBL] [Abstract][Full Text] [Related]
37. Comparison of serum markers in first-trimester down syndrome screening.
Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
Dhaifalah I; Májek O
Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
[TBL] [Abstract][Full Text] [Related]
39. First trimester risk assessment for trisomy 21 in twin pregnancies combining nuchal translucency and first trimester biochemical markers.
Prats P; Rodríguez I; Comas C; Puerto B
Prenat Diagn; 2012 Oct; 32(10):927-32. PubMed ID: 22752980
[TBL] [Abstract][Full Text] [Related]
40. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
